Use of Psychotropic Medications in Athletes: Clinical and Legal Aspects - Narrative review
DOI:
https://doi.org/10.12775/QS.2026.50.68109Keywords
sport psychiatry, psychotropic medications in athletes, mental health disorders in athletes, WADA regulations, Therapeutic Use Exemption (TUE)Abstract
Background:
Mental health disorders are increasingly recognized among athletes and may affect performance, well-being, and career longevity. Pharmacological treatment is often required; however, the use of psychotropic medications in athletes raises specific clinical concerns related to safety, performance, and adverse effects, as well as legal issues associated with anti-doping regulations.
Aim:
The aim of this narrative review was to summarize evidence on the clinical safety, performance-related effects, and legal implications of psychotropic medication use in athletes, with emphasis on anti-doping regulations.
Materials and Methods:
A narrative review of the scientific literature was conducted using publications from PubMed, clinical guidelines, and official documents from the World Anti-Doping Agency (WADA). Original studies, systematic reviews, meta-analyses, clinical guidelines, and regulatory documents addressing psychotropic medication use in athletic populations were included. Articles focusing exclusively on non-athletic populations without relevance to physical performance or regulatory aspects were excluded.
Results:
Available evidence indicates that selective serotonin reuptake inhibitors (SSRIs), bupropion, atomoxetine, and melatonin are among the most frequently preferred pharmacological options in athletes suffering from mental health disorders such as depression, ADHD and insomnia due to their favorable safety profiles and limited impact on physical and cognitive performance. Stimulant medications, although recommended as first-line therapy for ADHD in the general population, require careful consideration in athletes because of regulatory restrictions and the need for Therapeutic Use Exemptions (TUEs). Available evidence on antipsychotic use in athletes is limited. Importantly, untreated mental health conditions were associated with poorer functional outcomes than those observed with appropriately monitored pharmacotherapy.
References
[1] Hammond, T., Gialloreto, C., Kubas, H., & Hap Davis, H., 4th (2013). The prevalence of failure-based depression among elite athletes. Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, 23(4), 273–277. https://doi.org/10.1097/JSM.0b013e318287b870
[2] Golding, L., Gillingham, R. G., & Perera, N. K. P. (2020). The prevalence of depressive symptoms in high-performance athletes: a systematic review. The Physician and sportsmedicine, 48(3), 247–258. https://doi.org/10.1080/00913847.2020.1713708
[3] Contreras, D. W., Granquist, M. D., & Martin, L. A. (2023). Stress, Sport Anxiety, Neuroticism, and Coping in Student-Athletes: Implications for Patient Mental Health. Journal of athletic training, 58(9), 733–739. https://doi.org/10.4085/1062-6050-0527.22
[4] Rogers, D. L., Tanaka, M. J., Cosgarea, A. J., Ginsburg, R. D., & Dreher, G. M. (2024). How Mental Health Affects Injury Risk and Outcomes in Athletes. Sports health, 16(2), 222–229. https://doi.org/10.1177/19417381231179678
[5] Reardon, C. L., Hainline, B., Aron, C. M., Baron, D., Baum, A. L., Bindra, A., Budgett, R., Campriani, N., Castaldelli-Maia, J. M., Currie, A., Derevensky, J. L., Glick, I. D., Gorczynski, P., Gouttebarge, V., Grandner, M. A., Han, D. H., McDuff, D., Mountjoy, M., Polat, A., Purcell, R., … Engebretsen, L. (2019). Mental health in elite athletes: International Olympic Committee consensus statement (2019). British journal of sports medicine, 53(11), 667–699. https://doi.org/10.1136/bjsports-2019-100715
[6] Currie, A., Gorczynski, P., Rice, S. M., Purcell, R., McAllister-Williams, R. H., Hitchcock, M. E., Hainline, B., & Reardon, C. L. (2019). Bipolar and psychotic disorders in elite athletes: a narrative review. British journal of sports medicine, 53(12), 746–753. https://doi.org/10.1136/bjsports-2019-100685
[7] Stillman, M. A., Glick, I. D., McDuff, D., Reardon, C. L., Hitchcock, M. E., Fitch, V. M., & Hainline, B. (2019). Psychotherapy for mental health symptoms and disorders in elite athletes: a narrative review. British journal of sports medicine, 53(12), 767–771. https://doi.org/10.1136/bjsports-2019-100654
[8] Yengo-Kahn, A. M., & Solomon, G. (2015). Are psychotropic medications associated with differences in baseline neurocognitive assessment scores for young athletes? A pilot study. The Physician and sportsmedicine, 43(3), 227–235. https://doi.org/10.1080/00913847.2015.1071638
[9] Reardon, C. L., & Creado, S. (2016). Psychiatric medication preferences of sports psychiatrists. The Physician and sportsmedicine, 44(4), 397–402. https://doi.org/10.1080/00913847.2016.1216719
[10] Pillinger, T., Howes, O. D., Correll, C. U., Leucht, S., Huhn, M., Schneider-Thoma, J., Gaughran, F., Jauhar, S., McGuire, P. K., Taylor, D. M., Young, A. H., & McCutcheon, R. A. (2023). Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. The lancet. Psychiatry, 10(11), 860–876. https://doi.org/10.1016/S2215-0366(23)00262-6
[11] Parise, G., Bosman, M. J., Boecker, D. R., Barry, M. J., & Tarnopolsky, M. A. (2001). Selective serotonin reuptake inhibitors: Their effect on high-intensity exercise performance. Archives of physical medicine and rehabilitation, 82(7), 867–871. https://doi.org/10.1053/apmr.2001.23275
[12] Watson, P., Hasegawa, H., Roelands, B., Piacentini, M. F., Looverie, R., & Meeusen, R. (2005). Acute dopamine/noradrenaline reuptake inhibition enhances human exercise performance in warm, but not temperate conditions. The Journal of physiology, 565(Pt 3), 873–883. https://doi.org/10.1113/jphysiol.2004.079202
[13] Roelands, B., Hasegawa, H., Watson, P., Piacentini, M. F., Buyse, L., De Schutter, G., & Meeusen, R. (2009). Performance and thermoregulatory effects of chronic bupropion administration in the heat. European journal of applied physiology, 105(3), 493–498. https://doi.org/10.1007/s00421-008-0929-x
[14] World Anti-Doping Agency. (2025). The Prohibited List 2025. Retrieved from https://www.wada-ama.org/en/prohibited-list#search-anchor (Access: 15/12/2025)
[15] World Anti-Doping Agency. (2025). The 2025 Monitoring Program. Retrieved from https://www.wada-ama.org/sites/default/files/2024-09/2025_list_monitoring_program_en_final_clean_11_september_2024.pdf (Access: 15/12/2025)
[16] Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O'Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., McIntyre, R. S., … Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar disorders, 20(2), 97–170. https://doi.org/10.1111/bdi.12609
[17] Attention deficit hyperactivity disorder: diagnosis and management, National Institute for Health and Care Excellence (NICE), Retrieved from https://www.nice.org.uk/guidance/ng87/chapter/Recommendations#adherence-to-treatment
[18] Canadian ADHD Practice Guidelines, Canadian ADHD Resource Alliance (CADDRA) Retrieved from: https://www.caddra.ca/wp-content/uploads/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf
[19] Groom, M. J., & Cortese, S. (2022). Current Pharmacological Treatments for ADHD. Current topics in behavioral neurosciences, 57, 19–50. https://doi.org/10.1007/7854_2022_330
[20] Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H. C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The lancet. Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
[21] Berezanskaya, J., Cade, W., Best, T. M., Paultre, K., & Kienstra, C. (2022). ADHD Prescription Medications and Their Effect on Athletic Performance: A Systematic Review and Meta-analysis. Sports medicine - open, 8(1), 5. https://doi.org/10.1186/s40798-021-00374-y
[22] Paul, M. A., Gray, G., Kenny, G., & Pigeau, R. A. (2003). Impact of melatonin, zaleplon, zopiclone, and temazepam on psychomotor performance. Aviation, space, and environmental medicine, 74(12), 1263–1270.
[23] Fitria, L., Ifdil, I., Muhammad Fahli Zatrahadi, Darmawati, D., Istiqomah, I., Nur Adila Wafiqoh Zulvi, … Rima Pratiwi Fadli. (2025). Counseling and mental health interventions in sports: A systematic review of current practices and outcomes. SPORT TK-EuroAmerican Journal of Sport Sciences, 14, 56. https://doi.org/10.6018/sportk.650531
[24] Lundqvist, C., Wig, J., & Schary, D. P. (2024). Swedish elite athletes' experiences of psychotherapy for mental health concerns provided by licensed psychologists and psychotherapists: a qualitative study. BMJ open sport & exercise medicine, 10(3), e002044. https://doi.org/10.1136/bmjsem-2024-002044
[25] Rosa, A. R., Reinares, M., Michalak, E. E., Bonnin, C. M., Sole, B., Franco, C., Comes, M., Torrent, C., Kapczinski, F., & Vieta, E. (2010). Functional impairment and disability across mood states in bipolar disorder. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 13(8), 984–988. https://doi.org/10.1111/j.1524-4733.2010.00768.x
[26] Charest, J., & Grandner, M. A. (2022). Sleep and Athletic Performance: Impacts on Physical Performance, Mental Performance, Injury Risk and Recovery, and Mental Health: An Update. Sleep medicine clinics, 17(2), 263–282. https://doi.org/10.1016/j.jsmc.2022.03.006
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Natalia Marta Bruska, Andrii Bilyk, Mateusz Kubicki, Adam Wolski, Przemysław Kołodziej, Maria Król, Bartłomiej Błaszkowski, Wiktoria Michnowska, Paweł Pustuła, Mieszko Czapliński
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 3
Number of citations: 0
